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H9c2 cellIn the present study, we report that somatostatin receptor 2 (SSTR2) plays a crucial role in modulation of β1AR
and β2ARmediated signaling pathways that are associatedwith increased intracellular Ca2+ and cardiac compli-
cations. In H9c2 cells, SSTR2 colocalizes with β1AR or β2AR in receptor speciﬁc manner. SSTR2 selective agonist
inhibits isoproterenol and formoterol stimulated cAMP formation and PKA phosphorylation in concentration de-
pendentmanner. In the presence of SSTR2 agonist, the expression of PKCα and PKCβwas comparable to the basal
condition, however SSTR2 agonist inhibits isoproterenol or formoterol induced PKCα and PKCβ expression, re-
spectively. Furthermore, the activation of SSTR2 not only inhibits calcineurin expression and its activity, but
also blocks NFAT dephosphorylation and its nuclear translocation. SSTR2 selective agonist abrogates isoprotere-
nol mediated increase in cell size and protein content (an index of hypertrophy). Taken together, the results de-
scribed here provide direct evidence in support of cardiac protective role of SSTR2 via modulation of Ca2+
associated signaling pathways attributed to cardiac hypertrophy.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Adrenergic receptors (ARs) are the prominent and most studied
members of G-protein coupled receptor (GPCR) family and have been
well characterized for their crucial role in cardiovascular complications
[1,2]. The activation of β1 and β2AR is associated with different patho-
physiological responses and illicit receptor speciﬁc role in heart failure
[3–6]. Several studies have described the activation of second messen-
ger cyclic-adenosine monophosphate (cAMP) by β1 and β2AR in recep-
tor speciﬁc manner [7]. Furthermore, cAMP dependent protein kinase
(PKA) induced the phosphorylation of phospholamban and cardiac con-
tractile protein via activation of β1AR but not of β2AR [8]. In addition,
over-expression of β1AR also induced hypertrophy and apoptosis in
cardiomyocytes [9,10]. Receptor coupling to different G proteins i.e.,
Gs and Gi is important in signal transduction [11–14]. β-ARs coupling
to Gs protein, regulation of adenylyl cyclase (AC) mediated cAMP/PKA
and consequent changes in Ca2+ related signaling cascades exert key
roles in cardiac contraction. Most importantly, Ca2+ mediated regula-
tion of myocyte contraction is intimately associated with β-ARs cou-
pling to AC. In addition to the changes in PKC isoforms, the best
studied process that serves in promoting cardiac hypertrophy is linkedergic receptor; Ca2+, calcium;
H, left ventricular hypertrophy;
inase A; PKC, Protein Kinase C;
1 604 822 3035.
ights reserved.with the Ca2+ regulated calcineurin dependent nuclear factor of activat-
ed T-cells (NFAT), dephosphorylation and its nuclear translocation.
The role of somatostatin (SST) in pathophysiological conditions in-
cluding neurological diseases, pituitary tumor, and breast cancer as
well as tumors of different origins is well established and undisputed
[15–19]. However, studies supporting the role of SST in the cardiovascu-
lar system such as in hypertrophy and contractile functions are limited
[20–22]. Furthermore, the clinical implication and physiological signiﬁ-
cance of SST in the cardiovascular system have not been well appreciat-
ed yet. We recently described the role of SST in the regulation of β-AR
mediated signal transduction in H9c2 cells [19]. SST binds to and acts
on ﬁve different receptor subtypes (SSTR1–5) which belong to GPCR
family and have been well characterized pharmacologically in various
target tissues [15]. These observations raise the question whether SST
modulates β-AR stimulated changes in signaling pathways directly via
activation of SSTR subtypes or indirectly via regulation of hormones or
growth factors to alleviate the loss of cardiac function is not well under-
stood. While SST plays a critical role in cardiac hypertrophy and heart
failure, receptor subtype associated with such role remains elusive
[22–26].
SSTR subtypes are present in variable density in cardiac cells or heart
tissues whereas very little is known pertaining to their function in car-
diac complications. SSTR2 induces apoptosis (cytotoxic effect) and cell
growth arrest (cytostatic effect) in cell speciﬁc manner and involves in
the regulation of Ca2+ homeostasis. Although, there is no direct evi-
dence of SSTR2 mediated regulation of L-type Ca2+ channels in cardiac
cells, SSTR2-selective agonists like MK 678 and BIM 23027 inhibit Ca2+
conductance in mouse anterior pituitary cells (AtT-20) that predomi-
nantly expresses L-type Ca2+ channels [27]. Similarly, rat SSTR2 upon
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inﬂux in RIN cells [28]. Given the ability of SSTR2 to inhibit Ca2+ inﬂux,
we speculate that SSTR2 activation could be beneﬁcial in cardiomyopa-
thy speciﬁcally via modulation of Ca2+ associated pathways which are
triggered by β1 and β2AR. To test this hypothesis, instead of directly
measuring the changes in intracellular Ca2+ levels, the present study
was undertaken to determine the role of SSTR2 in modulation of β1
and β2AR mediated Ca2+ associated signaling pathways including
cAMP/PKA, PKCα/β, calcineurin and NFAT which functions in articulat-
ed manner in cardiac tissue. We also analyzed the changes in cell size
and total protein content in response to the activation of β-ARs and
SSTR2. The results described here uncovered the crucial role of SSTR2
in the regulation of signaling pathwayswith potential therapeutic inter-
vention in regulating factors contributing in cardiac complications in-
cluding cardiomyopathy and heart failure.
2. Materials and methods
2.1. Chemicals and reagents
H9c2 rat fetal cardiomyocytes were kindly provided by Dr. David
Fedida, UBC. SSTR2 agonist L-779976 was kindly obtained from Dr. SP
Rohrer, MERCK. Isoproterenol hydrochloride, formoterol hemifumarate,
CGP 20712 dihydrochloride and ICI-118,551 hydrochloride were pur-
chased from TOCRIS Bioscience (Ellisville, MO). Antibody against β-
actin was purchased from Sigma-Aldrich, Inc., St. Louis, MO. Anti-β1AR
goat polyclonal antibody was purchased from TOCRIS Bioscience
(Ellisville, MO) and mouse monoclonal β2AR antibody was purchased
from Abcam (Cambridge, MA). Rabbit polyclonal antibodies directed
against phospho and total-PKA, NFAT and PKCβ were obtained from
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Rabbit polyclonal anti-
bodies against phospho- and total-ERK1/2 and anti-PKCα were
purchased from Cell Signaling Technology (Danvers, MA). Mouse
monoclonal antibody against calcineurinwas procured fromBD Labora-
tories. Fluorescein/Cy3 and HRP-conjugated goat anti-mouse and goat
anti-rabbit secondary antibodies were purchased from Jackson
ImmunoResearch Laboratories, Inc. (West Grove, PA). cAMP assay kit
was purchased from BioVision, Inc. CA, USA. Protein A/G-Agarose
beads were purchased from Calbiochem, EMD Biosciences (Darmstadt,
Germany). Calcineurin assay kit was procured from EMD Millipore
(Darmstadt, Germany). Reagents for electrophoresis were purchased
fromBio-Rad Laboratories (Mississauga, ON). Dulbecco'smodiﬁed Eagle's
medium, Trypsin–EDTA, and Dulbecco's Phosphate Buffered Saline
(D-PBS) were purchased from Gibco, Invitrogen (Burlington, ON,
Canada). Other reagents of AR gradewere procured from various sources.
2.2. Cell culture
H9c2 rat fetal cardiomyocytes were grown in Dulbecco's modiﬁed
Eagle's high glucose medium (DMEM) containing 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin under humid atmosphere
at 37 °C. Cell cultures between passages 3 to 5 at 70–80% conﬂuency
were used for each experiment.
2.3. Immunocytochemistry
SSTR2 and βAR subtype colocalization in H9c2 cells was determined
as described earlier [29,30]. Brieﬂy, cells were grown on poly-D-Lysine
coated coverslips and ﬁxed with 4% paraformaldehyde for 20 min on
ice. After three washes with PBS, the cells were incubated with 5% nor-
mal goat serum in PBS for 1 h at room temperature followed by over-
night incubation with antibodies for SSTR2 (1:500) and β1AR or β2AR
(1:300) in 1% normal goat serum in PBS at 4 °C. Following three subse-
quent washes, the cells were then incubated with Cy3 and/or FITC con-
jugated secondary antibodies for 1 h at room temperature. Coverslips
were mounted onto microscope slides and images were observedunder Leica Confocal microscope. For NFAT expression, H9c2 cells
were treated with receptor speciﬁc agonist alone or in combination
for 30 min at 37 °C and processed for immunocytochemistry using
NFAT speciﬁc antibody.
2.4. Co-immunoprecipitation and Western blot analysis
H9c2 cells were treated with L-779976, isoproterenol or formoterol
alone or in combination for 30 min at 37 °C and cell membrane was
prepared in homogenizing buffer as previously described [31]. Mem-
brane pellets were washed and resuspended in 20 mM Tris–HCl,
pH 7.5 in the presence of protease inhibitors (1:100). Samples were in-
cubated with β-AR speciﬁc antibody (1:500) overnight at 4 °C on the
rocking shaker. 25 μl of protein A/G-agarose beads was added to each
tube to immunoprecipitate antibody for 2 h at 4 °C. Beads were then
washed three times in PBS and solubilized in Laemmli sample buffer
(Bio-Rad) containing 5% β-mercaptoethanol. The fractionated proteins
were transferred to a 0.2 μMnitrocellulosemembrane in transfer buffer.
Membranes were blottedwith anti-SSTR2 antibody (dilution 1:500) for
the detection of SSTR2. ForWestern blot analysis, H9c2 cells were treat-
ed with L-779976 (10 nM) for 5, 10, 20 and 30 min or with different
concentrations of L-779976 (1, 10 and 20 nM) for 15 min at 37 °C. In
addition, H9c2 cells were also treated with isoproterenol or formoterol
(1 μM) in combination with increasing concentrations of L-779976
(0–50 nM) for 15 min at 37 °C. Treatments were terminated by adding
ice-cold PBS and cells were lysed by using RIPA buffer (containing
50 mMTris–HCl, 150 mMsodium chloride, 1% igepal CA-630, 0.5% sodi-
um deoxycholate, and 0.1% sodium dodecyl sulfate (SDS), pH 8.0).
Equal amounts of protein were separated by 10% SDS-polyacrylamide
gel electrophoresis and transferred onto a nitrocellulose membrane.
The membrane was blocked with 5% nonfat dry milk in TBS-T (pH 7.6,
20 mM Tris HCl, 137 mM NaCl and 0.2% Tween 20) and subsequently
incubated with polyclonal antibody against phospho or total-ERK1/2,
PKA or NFAT and PKCα and β at 4 °C overnight. After washing, the
membrane was then incubated with HRP-conjugated secondary anti-
bodies and detected by using enhanced chemiluminescence detection
reagent (GEHealthcare, Baie d'Urfe QC) according to themanufacturer's
instructions.
2.5. Adenylyl cyclase activity assay
H9c2 cellswere grown till N70% cell conﬂuency in 6well culture plates
and cAMP levelswere estimated by enzyme linked immunosorbent assay
(ELISA). Brieﬂy, cells were incubated for 30 min in the presence of 20 μM
forskolin (FSK) and 0.5 mM 3-isobutyl-1-methylxanthine with receptor
speciﬁc agonist L-779976, isoproterenol, formoterol, CGP 20712 and ICI
118,551 alone or in combination at 37 °C. cAMP was determined by im-
munoassay using a cAMP Kit from BioVision, Inc. CA, USA according to
the manufacturer's guidelines.
2.6. Calcineurin activity assay
Colorimetric assay for measuring cellular calcineurin (PP-2B) phos-
phatase activity was performed as per the manufacturer's instruction.
Brieﬂy, H9c2 cells were treated with L-779976, isoproterenol and
formoterol alone or in combination for 30 min at 37 °C. Cells were
lysed by using lysis buffer (provided in the kit) and high speed superna-
tant was further desalted using pre-packed columns (Bio-Rad Laborato-
ries). Total protein content in the samples was determined by using
Bradford assay and samples were normalized. ELISA was performed to
determine the phosphate released by calcineurin phosphatase as per
the manufacturer's instructions. Calcineurin activity was calculated as
[Calcineurin Activity = Total Activity − Activity in the presence of
EGTA Buffer] and/or [Calcineurin Activity = Activity in the presence
of Okadaic Acid − (Activity in the presence of Okadaic Acid + EGTA)].
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H9c2 cells grown to 60–70% conﬂuency were serum deprived for
24 h and treated with SSTR2 agonist L-779976 (500 nM) and β1AR ag-
onist isoproterenol (10 μM) alone or in combination for 48 h in the
presence of 1% FBS [32]. Cells were imaged by using the IncuCyte
Zoom system from Essen Bioscience. Images were captured every 2 h
interval for 48 h using a 10× objective. For total protein content, cells
were treated as indicated in the presence of 5% FBS and trypsinized
cells were centrifuged and lysed with 100 μl lysis buffer. Protein con-
centration in total cell lysates was measured using the Bradford assay
(Sigma-Aldrich, Inc., St. Louis, MO) with bovine serum albumin as stan-
dard. Protein content per cell was determined by dividing the total pro-
tein with the cell number for each condition.
2.8. Statistical analysis
The data was analyzed using GraphPad Prism 4.0. The data was sta-
tistically analyzed using one-way ANOVA and the post-hoc Dunnett's or
Bonferroni's test was applied according to the experimental conditions
to compare treatments. Signiﬁcant statistical differences were taken atFig. 1. Interaction between SSTR2 and β1AR or β2AR in H9c2 cells. Immunoﬂuorescence photo
β1AR or β2AR positive H9c2 cells are shown in red color in panels A and B. SSTR2 like immunore
yellowor orange color inmerged images (panelsA andB). DAPI represents nuclear staining in bl
strong colocalization between SSTR2 and β-ARs in perinuclear region of the cells. SSTR2 was h
treated cells as indicated. Note the signiﬁcant loss of SSTR2 expression in β1AR immunoprecip
expression was increased in β2AR immunoprecipitate upon SSTR2 speciﬁc agonist L-779976 an
was observed in empty beads (in the absence of β-AR antibodies) indicating the speciﬁcity ofp values b0.05. Results are presented as mean ± SD unless otherwise
stated.3. Results
3.1. Colocalization of somatostatin receptor 2 and β-adrenergic receptors in
H9c2 cells
As shown in Fig. 1A and B, H9c2 cells exhibit relatively higher ex-
pression of β2AR than β1AR. Receptor like immunoreactivity was pre-
dominantly conﬁned intracellularly with strong expression in
perinuclear zone. Like βARs, SSTR2 like immunoreactivity was also ob-
served intracellularly. β1AR (A) and β2AR (B) displayed variable degree
of colocalization with SSTR2 in H9c2 cells. β1AR colocalized with SSTR2
strongly in perinuclear zone with weak colocalization in the rest of the
intracellular regions. SSTR2 and β2AR exhibited widespread cytoplasmic
colocalization. Most importantly, no uniform pattern of colocalization be-
tween SSTR2 and β-AR subtypes was observed. As illustrated, some cells
displayed strong colocalizationwhile other cellswere either devoid or ex-
hibit weak colocalization.micrographs illustrating the colocalization of SSTR2 with β1AR or β2AR in H9c2 (A and B).
activity in H9c2 cells is shown in green and cells displaying colocalization are indicated by
ue color in both panels. Note the signiﬁcantly variable intensity of receptor expressionwith
ighly expressed in β1AR (C) and β2AR (D) immunoprecipitates prepared from control and
itate upon treatment with isoproterenol in comparison to control (C). In contrast, SSTR2
d/or formoterol treatment (D). No expression of SSTR2 at the expected molecular weight
interaction (E). Scale bar = 10 μm.
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We next determined the expression of SSTR2 in β1AR (Fig. 1C) and
β2AR (Fig. 1D) immunoprecipitates to anticipate any possible interac-
tion between these receptors. H9c2 cells were treated with SSTR2 and
β1AR or β2AR selective agonist alone or in combination for 30 min at
37 °C. Membrane fraction prepared was immunoprecipitated with spe-
ciﬁc antibodies againstβ1AR orβ2AR and immunoblottedwith antibody
against SSTR2. As shown in Fig. 1C, SSTR2 was highly expressed in β1AR
immunoprecipitate prepared from control and treated cells at the ex-
pected molecular size of N100 kDa. SSTR2 expression in β1AR immuno-
precipitate was comparable to basal expression upon treatment with L-
779976 alone or in combination with isoproterenol however relatively
lower in cells treated with isoproterenol.
In comparison to β1AR immunoprecipitate, the expression of SSTR2
(N100 kDa) was comparatively weak in β2AR immunoprecipitate
prepared from control cells, whereas increased upon treatment with
L-779976 (Fig. 1D). In contrast, treatment with formoterol alone or in
the presence of L-779976 displayed comparable SSTR2 expression albeit
relatively higher than control. To ascertain the speciﬁcity of Co-IPmem-
brane fraction incubated in the absence of primary antibodies or blank
beads were devoid of SSTR2 expression (Fig. 1E). These results are
possible indication in support that SSTR2/β-ARs might exist in a
heteromeric complex in H9c2 cells.
3.3. SSTR2mediated inhibition of cAMP is enhanced in the presence of β-AR
antagonist
We recently described that SST inhibits β1/β2AR stimulated cAMP in
H9c2 and HEK-293 cells cotransfected with SSTR5 and βARs [19,29,30].
Interestingly, SST mediated inhibition of cAMPwas further enhanced in
the presence of β1AR or β2AR antagonist [19,29,30]. Accordingly, we
next studied whether inhibitory effect of SST on FSK stimulated cAMP
is mediated by SSTR2 in H9c2 cells. Cells were treated with SSTR2 spe-
ciﬁc agonist L-779976, isoproterenol and formoterol alone or in combi-
nation for 30 min at 37 °C in the presence of FSK and processed for
cAMP levels. As illustrated in Fig. 2, FSK stimulated cAMPwas inhibitedFig. 2. Receptors coupling to adenylyl cyclase. H9c2 cells were incubated with 20 μM FSK
with or without SSTR2, β1AR and β2AR agonists or antagonists alone or in combination at
37 °C for 30 min. cAMP formation was inhibited in the presence of SSTR2 agonist and
enhanced upon treatment with β-AR agonists. Increased cAMP formation induced by
β-AR agonists was signiﬁcantly abrogated in the presence of SSTR2 agonist. Note the sig-
niﬁcantly augmented effect of SSTR2 on the inhibition of FSK stimulated cAMP upon β2AR
inactivation by antagonist ICI. Data are shown as % inhibition/activation of FSK stimulated
cAMP formation. Data analysis was done by using ANOVA and post-hoc Bonferroni's to
compare against basal (*, p b 0.05), isoproterenol treatment (#, p b 0.05) and formoterol
treatment (@, p b 0.05); n = 3.by 19.51 ± 0.57% in the presence of SSTR2 agonist (10 nM). Converse-
ly, FSK stimulated cAMP was signiﬁcantly enhanced by 29.42 ± 0.88%
and 66.16 ± 2.3% in the presence of β1AR and β2AR speciﬁc agonists
respectively. SSTR2 agonist in combination with isoproterenol or
formoterol resulted in signiﬁcant attenuation in β-AR induced cAMP
levels in H9c2 cells (4.04 ± 0.85% and 39.65 ± 0.82%) respectively. Of
note, FSK stimulated cAMP was unaffected in the presence of β-AR
speciﬁc antagonist, however, L-779976mediated inhibition of FSK stim-
ulated cAMP was signiﬁcantly enhanced in the presence of β-AR antag-
onist. As illustrated in Fig. 2, in the presence of SSTR2 agonist in
combination with ICI or CGP, FSK stimulated cAMP was inhibited by
20.76 ± 2.5% and 30.90 ± 2.5% respectively. This inhibition was signif-
icantly different in the presence of SSTR2 agonistwith ICI in comparison
to CGP selective antagonist for β1AR and β2AR respectively. These
results suggest that blocking of β-ARs potentiates SSTR2 coupling to
AC with pronounced inhibitory effect on cAMP formation.
3.4. Concentration and time dependent effects of SSTR2 activation on PKA
phosphorylation
As reported previously, changes in cAMP and intracellular Ca2+
levels are directly associated with the activation of PKA. Therefore, we
next determined the status of PKA phosphorylation in H9c2 cells.
SSTR2 speciﬁc agonist L-779976 displayed time and concentration de-
pendent inhibitory effects on PKA phosphorylation (Fig. 3A). Despite
higher PKA activation in basal condition, L-779976 (10 nM) inhibited
PKA phosphorylation signiﬁcantly at 5, 10 and 20 min treatments,
which was recovered to basal level following prolonged treatment for
30 min. As shown in Fig. 3A, cells treated with 1, 10 and 20 nM of
L-779976 for 15 min at 37 °C resulted in signiﬁcantly lower phospho-
PKA levels in comparison to control without any noticeable changes at
different concentrations.
To determinewhether activation of SSTR2 negatively regulates β1AR
or β2AR mediated PKA phosphorylation, cells were treated with SSTR2
agonist L-779976 (1–50 nM) in combinationwithβ1AR orβ2AR speciﬁc
agonist (1 μM) for 15 min at 37 °C. As illustrated in Fig. 3B and C,
phospho-PKA level observed in the presence of isoproterenol and
formoterol (1 μM) alone or in combination with increasing concentra-
tions of L-779976 remained relatively comparable to control without
any signiﬁcant changes. These results indicate that PKA phosphoryla-
tion and cAMP inhibition are receptor speciﬁc and independently regu-
lated process.
3.5. SSTR2 activation inhibits PKCα and PKCβ expression in H9c2 cells
PKC isozymes exert hypertrophic stimuli in cardiac cells and in-
creased expression of PKCα is associated with heart failure [33]. Fur-
thermore, the inhibitors of PKC have been implicated to ameliorate
hypertrophy [33]. To examine whether SSTR2 mediated inhibition of
cAMP/PKA was also involved in the regulation of PKC, the expression
levels of PKCα and β were determined in the presence of L-779976 in
time and concentration dependent manner. H9c2 cells were treated
with L-779976 (10 nM) for 0–30 min andwith different concentrations
(1–20 nM) for 15 min at 37 °C. As shown in Fig. 4A, the expression
of PKCα and β was not changed in cells either treated with different
concentrations or times with L-779976.
To assess the potential role L-779976 on isoproterenol and formoterol
mediated changes in PKCα and β, H9c2 cells were treated with different
concentrations of L-779976 (1–50 nM) with isoproterenol or formoterol
(1 μM) for 15 min at 37 °C. As shown in Fig. 4B, PKCα expressionwas en-
hanced signiﬁcantly in the presence of isoproterenolwithout any discern-
ible changes in PKCβ expression. Increasing concentration of SSTR2
agonist L-779976 in combination with isoproterenol (1 μM) resulted in
inhibition of PKCα in a concentration dependentmannerwhen compared
to control as well as isoproterenol treated cells. In contrast, PKCβ expres-
sion was comparable to control in cells treated with isoproterenol alone
Fig. 3. Effect of SSTR2 agonist on isoproterenol and formoterol activated PKA. H9c2 cells were treatedwith SSTR2 agonist L-779976 (10 nM) for 0–30 min or with different concentrations
(1–20 nM). Cells were also treated in combination with β-AR agonist (1 μM) in the presence of different concentrations of SSTR2 agonist (0–50 nM) as indicated for 15 min at 37 °C.
(A) SSTR2 speciﬁc agonist inhibits PKA phosphorylation in time or concentration dependent manner. (B and C) The status of phospho-PKA was comparable to control in the presence
of isoproterenol and formoterol alone or in combination with SSTR2 agonist. Data represents three independent experiments and analyzed by using ANOVA and post-hoc Dunnett's
test to compare against basal (*, p b 0.05).
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changes at different concentrations (Fig. 4B, bottom panel).
As shown in Fig. 4C, PKCα level was comparable to basal in cells
treated with formoterol (1 μM) with or without L-779976. Conversely,
L-779976 inhibited formoterol induced activation of PKCβ in aFig. 4.Differential regulation of PKCα or β isoforms by β-ARs in H9c2 cells is inhibited by SSTR2
in Fig. 3. Cells treated with different concentrations or times in the presence of SSTR2 agonist L
control, isoproterenol treatment enhanced the expression of PKCα (B upper panel) with no si
isoproterenol induced PKCα expression in the presence of SSTR2 agonist signiﬁcantly different
PKCβ expressionwith no signiﬁcant effect on PKCα. Note the signiﬁcant inhibitory effect of SSTR
on PKCα (C, upper panel). Data represents three independent experiments and data analy
(*, p b 0.05) or β-AR agonist treatment alone (#, p b 0.05).concentration dependentmanner (Fig. 4C, bottom panel) signiﬁcantly
in comparison to control and formoterol treated cells. Interestingly,
these observations uncovered distinct effects of β1 and β2AR activa-
tion on PKC isoforms. Most importantly, SSTR2 selective agonist in-
hibits changes in PKC isoforms induced in AR speciﬁc manner.agonist. H9c2 cells were treatedwith L-779976, isoproterenol and formoterol as described
-779976 displayed no signiﬁcant effect on PKC (α or β) expression (A). In comparison to
gniﬁcant effect on PKCβ (B lower panel). Note the concentration dependent inhibition of
from control and isoproterenol treatment. (C) In contrast, formoterol treatment enhanced
2 inmodulation of formoterol induced expression PKCβ (C, lower panel)without any effect
sis was done by using ANOVA and post-hoc Bonferroni's test to compare against basal
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activity in H9C2 cells
Like cAMP/PKA/PKC, the activity of calcineurin in cardiac tissue and
cells is also regulated by Ca2+. To ascertain the role of SSTR2, the phos-
phatase activity of calcineurin and its expression was determined in
H9c2 following treatment with SSTR2 and β-ARs speciﬁc agonists iso-
proterenol and formoterol. As shown in Fig. 5A, the phosphatase activity
of calcineurin was inhibited by ~40% in the presence of SSTR2 speciﬁc
agonist in comparison to control. Isoproterenol and formoterol en-
hanced calcineurin phosphatase activity by ~1.5 and ~1.25 folds respec-
tively when compared to control. SSTR2 agonist in combination with
isoproterenol and formoterol abrogated calcineurin phosphatase activi-
ty by ~50–60% which was comparable to L-779976 treatment alone
whereas signiﬁcantly different in comparison to control.
To further correlate the phosphatase activity, calcineurin expression
was determined byWestern blot analysis following treatments with re-
ceptor speciﬁc agonist in H9c2 cells. As illustrated in Fig. 5B, in compar-
ison to control, calcineurin expression was inhibited upon treatment
with L-779976. In contrast, calcineurin expressionwas enhanced signif-
icantly in cells treated with isoproterenol and formoterol alone. Consis-
tentwith the phosphatase activity, β-ARmediated increased expression
level of calcineurin was signiﬁcantly inhibited in the presence of L-
779976 when used in combination with isoproterenol and formoterol.
These results indicate that β-AR activated calcineurin expression and
phosphatase activity are diminished upon activation of SSTR2 due to
the expected inhibition of Ca2+ inﬂux in H9c2 cells.
3.7. SSTR2 mediated NFAT phosphorylation and inhibition of its nuclear
translocation
Calcineurin mediated NFAT dephosphorylation and its nuclear
translocation have been linked in propagating hypertrophy. We sought
to determine whether SSTR2 mediated inhibition of β-AR inducedFig. 5. SSTR2 negatively regulates calcineurin activity and expression inH9c2 cells. H9c2 cells w
for calcineurin phosphatase activity as described in the Materials and methods section. (A) Pho
whereas SSTR2 agonist exhibited inhibition of phosphatase activity. Note the signiﬁcant effect of
or formoterol. (B) To determine the expression level of calcineurin, lysate prepared from cont
mediated enhanced expression of calcineurin immunoreactivity upon SSTR2 agonist treatment a
and data analysis was done by using ANOVA and post-hoc Dunnett's test to compare against bcalcineurin expression and phosphatase activity also blocks NFAT
dephosphorylation and its nuclear translocation. H9c2 cells were treat-
ed with SSTR2 speciﬁc agonist in time (0–30 min) and concentration
(1, 10 and 20 nM) dependent manner at 37 °C and processed to
determine the status of NFAT phosphorylation. As shown in Fig. 6A,
cells exposed to L-779976 exhibited signiﬁcant increase of NFAT phos-
phorylation in time and concentration dependent manner. As shown,
the maximal activation of NFAT was observed at 5 and 10 min treat-
ments with SSTR2 agonist (10 nM) or in the presence of 10 nM concen-
tration of SSTR2 agonist for 15 min treatment.
To determine whether SSTR2modulates β1 and β2AR induced NFAT
phosphorylation, H9c2 cells were treated with different concentrations
of L-779976 (1–50 nM) with isoproterenol or formoterol (1 μM).
As shown, the NFAT phosphorylation was inhibited upon treatment
with isoproterenol and formoterol alone (Fig. 6B and C). Furthermore,
L-779976 ameliorates isoproterenol and formoterol induced inhibition
of NFAT phosphorylation in concentration dependent manner and re-
sulted in signiﬁcant increase of phospho-NFAT levels when compared
to control and cells treated with isoproterenol and formoterol alone
(Fig. 6C). Interestingly, L-779976 mediated changes in the phospho-
NFAT levels in the presence of formoterol were more pronounced in
comparison to isoproterenol treatment.
3.8. SSTR2 agonist block NFAT nuclear translocation
To determine whether SSTR2 mediated activation of NFAT phos-
phorylation is also associatedwith the inhibition of NFAT nuclear trans-
location, H9c2 cells were processed for nuclear expression of NFAT. As
shown in Fig. 6, control (D) and cells treated with L-779976 (E)
displayed predominant cytoplasmic expression of NFAT. Conversely,
cells treated with isoproterenol (F) and formoterol (G) resulted in en-
hanced nuclear localization of NFAT, which was signiﬁcantly inhibited
in the presence of SSTR2 agonist (H and I). Nuclear translocation of
NFAT was relatively higher upon treatment with isoproterenol whenere treatedwith SSTR2 agonist L-779976 (10 nM) for 30 min and cell lysatewas processed
sphatase activity was enhanced in the presence of isoproterenol or formoterol treatments
SSTR2 agonist on inhibition of calcineurin activity induced in the presence of isoproterenol
rol and treated cells was processed for Western blot analysis. Note the inhibition of β-AR
lone or in combinationwithβ-AR agonist. Data represents three independent experiments
asal (*, p b 0.05).
Fig. 6. β-ARs induced dephosphorylation and nuclear translocation of NFAT is blocked in the presence of SSTR2 agonist. H9c2 cells were treatedwith SSTR2 agonist (10 nM) for 0–30 min
aswell aswith different concentrations (1–20 nM) for 15 min at 37 °C. SSTR2 agonist enhancedNFAT phosphorylation in time and concentration dependentmannerwithmaximal effect
at 10 min and 10 nM respectively (A). In comparison to control, isoproterenol or formoterol treatment alone elicits NFAT dephosphorylation (B and C). Increasing concentration of SSTR2
agonist L-779976 blocked isoproterenol or formoterol induced NFAT dephosphorylation and signiﬁcantly enhanced phospho-NFAT levels (B and C) (*, p b 0.05 against basal and #,
p b 0.05 against β-AR agonist treatment alone; n = 3). (D and E) To determine NFAT nuclear translocation, immunocytochemistry was performed in control and treated H9c2 cells.
Control and cells treatedwith SSTR2 agonist displayedweak to negligible nuclear expression ofNFAT. Note the increased nuclear expression of NFAT uponβ1AR or β2AR activation (panels
F andG). SSTR2 agonist in combinationwith isoproterenol (H) or formoterol (I) signiﬁcantly blockedNFAT nuclear translocation. Arrows in representative panels indicate nuclear expression of
NFAT. Scale bar = 10 μm.
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dephosphorylation and its nuclear translocation and attest to the
therapeutic implication of SSTR2 in abrogating NFAT induced cardiac
hypertrophy.
3.9. SSTR2 activation inhibits isoproterenol induced cell size and protein
content in H9c2 cells
In cardiac hypertrophy, increased cardiac pump function and
decreased ventricular wall tension are associated with growth of indi-
vidualmyocytes. Furthermore, sustained and prolongedmyocardial hy-
pertrophy leads to heart failure. To ascertain the impact of changes in
Ca2+ regulated signaling pathways, cell size and protein content were
determined. H9c2 cells were treated with isoproterenol (5, 10 and
20 μM) alone or in combination with L-779976 (50 nM and 500 nM)for 48 h and processed for cell size analysis by employing two ap-
proaches i.e., morphological analysis and total protein estimation. As
described in Fig. 7A, cells with or without SSTR2 speciﬁc agonist
displayed comparable sizewithout any noticeable changes at the differ-
ent time points. In comparison, cells treated with isoproterenol
displayed signiﬁcant increase in the cell size over the increasing time
period when compared to control or cells treated with SSTR2 agonist.
Importantly, isoproterenol induced increase in cell size was abrogated
in the presence of L-779976.
We also analyzed the concentration dependent effect of isoprotere-
nol and SSTR2 agonist alone or in combination on total protein content
per 106 cells using Bradford assay (Fig. 7B and C). Total protein content
of H9c2 cellswas signiﬁcantly increased upon treatmentwith isoproter-
enol in concentration dependent manner whereas decreased in the
presence of L-779976 (50 or 500 nM). Interestingly, isoproterenol (5,
Fig. 7.Morphological changes in cell size upon receptor activation. (A) H9c2 cells were treated with isoproterenol (10 μM) in the absence or presence of L-779976 (500 nM) for 48 h. Cells were imaged by using the IncuCyte Zoom system every 2 h
interval for 48 h using 10× objective. In comparison to control or L-779976, cells treatedwith isoproterenol displayed increased cell size (arrows). Isoproterenol mediated increase in cell size was blocked in the presence of SSTR2 selective agonist L-
779976 and majority of cells displayed normal morphology. (B and C) Total protein content in H9c2 cells was determined by using Bradford assay following treatment with isoproterenol and SSTR2 speciﬁc agonist alone or in combination in the
presence of 5% FBS. Decreased total protein content was observed upon treatment with SSTR2 speciﬁc agonist (50 or 500 nM) in comparison to control (B). Note that the presence of SSTR2 speciﬁc agonist (50 or 500 nM) signiﬁcantly blunted












Fig. 8. Schematic representation of SSTR2mediated regulation of β-ARs/Ca2+ dependent signaling pathways. SSTR2 activation inhibits β-ARmediated cAMP formation and Ca2+ inﬂux in
the cells and regulates calcineurin phosphatase activity. Inhibition of calcineurin phosphatase activity in turns maintains NFAT in phosphorylated state and abrogates its nuclear translocation.
Overall, the regulation of these upstream checkpoints leads to the inhibition of pro-hypertrophic transcriptional factor activation in the nucleus. Figure was constructed by using the online
pathway builder from Protein Lounge (http://www.proteinlounge.com).
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niﬁcantly blunted in the presence of SSTR2 speciﬁc agonist (50 or
500 nM) (B and C). These results suggest that SSTR2 mediated inhibi-
tion hypertrophy might be exploited as therapeutic intervention in
cardiac complications or heart failure.
4. Discussion
Deregulation of Ca2+ associated interconnected complex signaling
cascades such as cAMP/PKA/PKC and nuclear transcription factors like
cAMP response element binding protein (CREB) and NFAT plays a criti-
cal role in cardiac hypertrophy and heart failure [34–37]. Most impor-
tantly, activation of cAMP/PKA in the presence of β-ARs supports the
receptor speciﬁc role in myocyte contractility. Furthermore, inhibition
of calcineurin and NFAT dephosphorylation with consequent blockade
of NFAT nuclear translocation serves as critical step in preventing cardi-
ac complications.We recently described that SSTmodulatesβ1ARmedi-
ated key signaling pathways associated with cardiac hypertrophy in
H9c2 cells [19]. However, SSTR subtype that might regulate such crucial
role of SST in cardiac cells is not well understood. In the present study,
we delineate the role of SSTR2 in modulation of β-AR mediated signal-
ing pathways which are associated with increased Ca2+ and cardiac
hypertrophy (Fig. 8). Our results provide direct evidence that SSTR2negatively regulates β-AR induced signaling. To our knowledge this is
the ﬁrst comprehensive description delineating the role of SSTR2 in
the regulation of Ca2+ associated intracellular signaling cascades
which play detrimental roles in cardiac complications.
Previous studies have also demonstrated that SST and its analogs
Octreotide and Lanreotide impart cardio-protective effect in the left
ventricular hypertrophy (LVH) [23,25,38,39]. The speciﬁc SSTR subtype
associated with cardiac protection is not well understood however,
Octreotide exhibits high afﬁnity binding to SSTR2 whereas, SST and its
analog mediated regulation of Ca2+ are speciﬁcally arbitrated by
SSTR2 [28]. These observations support that SSTR2 is the prominent re-
ceptor subtype of the family which might play beneﬁcial role in cardiac
complications. We here demonstrate that SSTR2 colocalized with β1AR
and β2AR in H9c2 cells and is expressed in β1AR and β2AR immunopre-
cipitates. The weak expression of SSTR2 in β1AR immunoprecipitate
upon isoproterenol treatment might indicate either preferential
homodimerization of β1AR. Furthermore, β1AR heterodimerization
with β2AR may trigger receptor internalization.
SSTRs are involved in the regulation of Ca2+ inward currents via
cAMP dependent and independent pathways and act directly on high-
voltage-dependent Ca2+ channels via Gα0 protein [15,40–43]. Previous
studies have shown increased calcium inﬂux inH9c2 cells in response to
β-AR agonists [44]. We found that SSTR2 agonist negatively regulates
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SSTR2 mediated inhibition of cAMP was enhanced in the presence
of β-AR antagonist. In contrast, SSTR2 agonist alone or in combination
with β-AR selective agonists maintained PKA phosphorylation compara-
ble to control in time and concentration dependent manner. We have
previously demonstrated that in heterologous system (β1AR/SSTR5
cotransfected HEK-293 cells), SSTR5 speciﬁc agonist treatment signiﬁ-
cantly enhanced PKAphosphorylation [30]. These results uncover distinct
G-proteins involved in heterologous system when compared to the cells
expressing these receptors endogenously. Whether or not SSTR2 func-
tions in a similar manner like SSTR5 with β-ARs in HEK-293 is not
known and needs to be determined. Our results indicate that the regula-
tion of cAMP and PKA phosphorylation are two independent processes. If
FSK imparts such distinct effects on cAMP regulation and downstream
signaling pathways including PKA phosphorylation warrants further
studies.
Previous studies have shown that certain markers of hypertrophy
like mRNA level of atrial natriuretic peptide (ANP), increased protein
synthesis, protein to deoxyribonucleic acid (DNA) ratio, and cell size
were induced upon PKCα activation [45,46]. Also, over-expression of
PKCα results in cardiac dysfunctions [47]. Like PKCα, another isoform
namely PKCβ is also critical in promoting hypertrophic growth in
cardiomyocytes [48,49]. In hypertension-induced heart failure rats, in-
creased PKCβ levels were observed whereas selective inhibition of
PKCβ improved cardiac function [48,49]. Angiotensin-receptor antago-
nist decreases PKCβ activation and results in improved cardiac hyper-
trophy [33,49]. Moreover, intracellular Ca2+ and lipid mediated
signaling activate PKC and consequently impaired cardiac function
[50]. In agreement with these observations, results presented here de-
scribe attenuation of β-AR mediated increased PKCα and β expression
in the presence of SSTR2 agonist in concentration dependent manner.
Most importantly, SSTR2 speciﬁc agonist does not exert any signiﬁcant
effect on PKCα and β expressionwhen used alone. These results strong-
ly emphasize the role of receptor heterodimerization in H9c2 cells and
attest to the distinct role of receptor complex in comparison to native
receptors. Furthermore, our results also uncovered selectivity and spec-
iﬁcity of SSTR2 in the regulation of β-AR mediated expression of PKC
isoforms and its inhibition in either condition.Whether direct interactions
between PKC isoforms exert any plausible role on receptor mediated sig-
naling pathways is not well understood. Taken in consideration, SSTR2
mediated inhibition of PKCα and β expression attests its beneﬁcial role
in cardiac complication andmight serve as a potential therapeutic target.
SSTR2 mediated inhibition of cAMP/PKA and PKCα/β leads us to
speculate that Ca2+ dependent calcineurin activity, NFAT dephosphory-
lation and its nuclear translocation are interdependent events regulated
by myriad of factors. In cardiac tissues, increased Ca2+ directly or indi-
rectly via activation of calcineurin plays an essential role in hypertrophy
and targeting this pathway has emerged as a possible therapeutic ap-
proach [51]. To further support these observations, we here describe
that SSTR2 regulates calcineurin expression and its activation (phos-
phate release) in H9c2 cells alone or in the presence of isoproterenol.
The inhibition of PKC, p38, andGi resulted in decreased basal NFAT tran-
scription [52] whereas ERK1/2 has been shown to activate NFAT in T-
lymphocytes and in COS cells [53]. Consistent with these observations,
we observed enhanced phospho-NFAT levels upon SSTR2 agonist treat-
ment in combination with either isoproterenol or formoterol and pro-
vided biochemical and morphological evidences that SSTR2 plays a
critical role in blocking NFAT dephosphorylation. Nuclear translocation
of NFAT by isoproterenol and formoterol was also signiﬁcantly
abolished upon activation of SSTR2.
Cardiac hypertrophy involves remodeling of myocytes at both mo-
lecular and cellular levels [54]. Speciﬁcally in pathological cardiac hy-
pertrophy, these changes result in lengthening of myocytes and
dilation along with impaired cardiac functions [54]. Left ventricular re-
modeling is dependent upon several factors including severity of the
pathological condition in patients and also to the extent of isoproterenoltreatment in the experimental animals [55]. Here, we demonstrate that
SSTR2 agonist treatment in H9c2 cells resulted in signiﬁcant blockade of
isoproterenol mediated cell size and protein content. Although further
studies arewarranted, however the potential role of SSTR2 as a negative
regulator of Ca2+ mediated signaling and hypertrophy cannot be
underestimated. Since, SSTR subtypes function in concert as heterodi-
mers, the role of other SSTR subtypes alone or in combination with
SSTR2 cannot be avoided from discussion and further studies are in
progress in this direction. Taken in consideration, targeting multiple
steps in the regulation of Ca2+ associated signaling regardless of molec-
ular mechanism involved, our results implicate SSTR2 as a pharmaco-
logical intervention in cardiac complications or heart failure. We
postulate that activating SSTR2 with concomitant blockade of β1AR in
the presence of speciﬁc antagonist might serve as a potential therapeu-
tic approach in the regulation of pathological hypertrophy.Acknowledgements
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